By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Sopra Steria recognised as “Leader” by NelsonHall for its ability to deploy GenAI in support of organisations’ operational transformation
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > Sopra Steria recognised as “Leader” by NelsonHall for its ability to deploy GenAI in support of organisations’ operational transformation
Sopra Steria recognised as “Leader” by NelsonHall for its ability to deploy GenAI in support of organisations’ operational transformation
News

Sopra Steria recognised as “Leader” by NelsonHall for its ability to deploy GenAI in support of organisations’ operational transformation

Last updated: 28/11/2025 4:36 PM
Published: 28/11/2025
Share
SHARE

PARIS, Nov. 28, 2025 /PRNewswire/ — Sopra Steria, a major player in the European tech sector, has been ranked among the leaders in NelsonHall’s latest 2025 NEAT assessment for “GenAI-Enabled Operational Transformation”, particularly in the “Overall” category.

- Advertisement -

This recognition underlines the Group’s ability to industrialise GenAI to support the operational transformation of its clients, delivering fast, measurable benefits while meeting the requirements of major public- and private-sector organisations.

- Advertisement -

In this edition of the NEAT, Sopra Steria is recognised as a Leader in several key categories:

- Advertisement -
  • GenAI-Enabled Operational Transformation – Overall
  • Developing Custom GenAI Solutions
  • GenAI Support for BPS Service Delivery
  • Understanding GenAI Requirements

A robust AI strategy focused on operational impact
These results highlight the strategic direction taken by Sopra Steria to make AI a cornerstone of its offering, its operating model, and the value it delivers to its clients. Since 2023, the Group has accelerated its momentum around GenAI through:

- Advertisement -
  • The deployment of internal and external industry-specific AI solutions
  • The creation of factories to support large-scale deployment within client organisations
  • The development of an ecosystem of AI start-ups and partners
  • The structuring of new dedicated service lines

These efforts directly translate into the Group’s ability to bring robust, secure GenAI solutions into production, rapidly generating ROI for its European clients.

- Advertisement -

Yves Nicolas, Director of the Group AI Programme at Sopra Steria, said: “NelsonHall’s recognition confirms that our AI strategy has reached maturity. We have deliberately chosen an impact-driven approach: understanding the real needs of our clients, developing trustworthy GenAI solutions, and, above all, industrialising them quickly to generate operational value where it is most needed. Being ranked as leaders in so many categories reflects the commitment of our teams and our ability to harness AI to deliver concrete, measurable and lasting transformation.”

- Advertisement -

Contact
Aurélien Flaugnatti
aurelien.flaugnatti@soprasteria.com 

- Advertisement -

Logo – https://mma.prnewswire.com/media/1861938/Sopra_Steria_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/sopra-steria-recognised-as-leader-by-nelsonhall-for-its-ability-to-deploy-genai-in-support-of-organisations-operational-transformation-302627749.html

- Advertisement -
Watch the FIFA Club World Cup 2025 Live for Free on Hisense Smart TVs
ARKS forays into the world of fragrances with the launch of its debut scent ‘ARKS Day’
Bitget GetAgent Lets You “Ask Satoshi” 17 Years Later
Octillion Achieves Solar-Powered Manufacturing at EV Battery System Facility in India
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
TAGGED:abilitydeployforgenaiitsleadernelsonhallnewsoperationalorganisationsrecognisedsoprasteriasupporttransformation
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Best Semaglutide For Weight Loss 2026: Is MEDVi the Best GLP-1 Supplier for a Sustainable Online Weight Loss Program?
Technology

Best Semaglutide For Weight Loss 2026: Is MEDVi the Best GLP-1 Supplier for a Sustainable Online Weight Loss Program?

GlobeNews Wire
GlobeNews Wire
28/12/2025
Abu Dhabi Autonomous Summit to define the future of smart mobility as part of Abu Dhabi Autonomous Week 2025
Bank of America Reports Fourth Quarter 2025 Financial Results
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
Nanjing Jiangbei New Area Issues Global Call for Talents
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?